Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi,Norbert Schmitz,Christopher Flowers,Fang-Shu Ou,David Cunningham,Michael Pfreundschuh,John F Seymour,Ulrich Jaeger,Thomas M Habermann,Corinne Haioun,Hervé Tilly,Herve Ghesquieres,Francesco Merli,Marita Ziepert,Raoul Herbrecht,Jocelyne Flament,Tommy Fu,Bertrand Coiffier,Daniel Sargent

doi:10.1182/blood.v128.22.4196.4196

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi, Norbert Schmitz + Show 17 more

Open Access

https://doi.org/10.1182/blood.v128.22.4196.4196

Copy DOI

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 1

Affiliation: Mayo Clinic, Asklepios Klinik St. Georg, Emory University, Royal Marsden Hospital, Saarland University, Peter MacCallum Cancer Centre, Medical University of Vienna, University of Rouen, Hôpital Lyon Sud, Ospedale Santa Maria, Leipzig University, Hôpital d'Hautepierre, Bristol-Myers Squibb (Switzerland)

#Advisory Committees #Entity's Board + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Full Text